QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 palisade-bio-q1-eps-459-misses-428-estimate

Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(4.59) per share which missed the analyst consensus estimate of $(4.28...

 maxim-group-reiterates-buy-on-palisade-bio-maintains-225-price-target

Maxim Group analyst Naz Rahman reiterates Palisade Bio (NASDAQ:PALI) with a Buy and maintains $22.5 price target.

Core News & Articles
Market-Moving News for May 1 st
05/01/2024 12:44:43

TGTX: 31% | TG Therapeutics shares are trading higher following a Q1 revenue beat and increased 2024 Briumvi US net product rev...

Core News & Articles
Market-Moving News for May 1st
05/01/2024 12:41:28

TGTX: 31% | TG Therapeutics shares are trading higher following a Q1 revenue beat and increased 2024 Briumvi US net product rev...

 why-palisade-bio-stock-is-up-today

Palisade Bio entered into a collaboration with Strand Life Sciences is aimed at advancing precision medicine for ulcerative col...

 sp-500-edges-lower-pacbio-shares-plunge

U.S. stocks traded mixed toward the end of trading, with the S&P 500 falling around 0.3% on Tuesday. The Dow traded up 0.0...

 why-skillsoft-shares-are-trading-lower-by-around-27-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter...

 maxim-group-maintains-buy-on-palisade-bio-adjusts-price-target-to-225-reverse-stock-split-115

Maxim Group analyst Naz Rahman maintains Palisade Bio (NASDAQ:PALI) with a Buy, adjusts target to $22.5 from $22.5 (reverse ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION